Novel Cellular Probe Technologies for Screening Anti-Viral Therapeutic Candidates on Multiple Platforms

COVID-19表明，新出现的病毒对人类健康构成严重威胁。在流行病迅速蔓延期间，需要用抗病毒药物和阻断组织损伤的药物紧急治疗受影响的个体。这一流行病突出表明，需要快速有效地筛选新的和重新利用的药物，以便有希望的治疗方法能够进入临床。在过去的20年里，BioStatus一直在发明，开发和制造创新试剂和分子探针，用于生物医学中基于细胞的分析，成像和筛选应用。我们为世界各地的客户提供iso9001:2015质量标准。作为一家创新型公司，我们力求在我们最擅长服务的领域产生积极影响——在我们的案例中，就是新疗法的发现管道。我们的项目目标是快速开发一个新的探针家族和现有探针的新组合。我们的荧光试剂经过化学设计，可以进入细胞，揭示病毒攻击所带来的变化。我们的专利技术使研究人员能够探索人类细胞对病毒攻击的反应，以及一种新的候选药物是否可以防止病毒感染造成的损害。最终目标是提供经过筛选和验证的药物，可以阻止疾病进展并避免长期健康后果。

COVID-19 has demonstrated that emerging viruses present acute threats to human health. During rapidly spreading epidemics, affected individuals need to be treated urgently with antivirals and agents that intercept tissue damage. The epidemic has highlighted the need for rapid and effective screening of both novel and repurposed agents so that promising therapeutics can enter the path to the clinic.For the last 20 years, BioStatus has been inventing, developing and manufacturing innovative reagents and molecular probes for cell-based analysis, imaging and screening applications in biomedicine. We supply customers all over the world to the ISO 9001:2015 quality standard. As an innovative company, we seek to make a positive impact in the area that we can best serve – in our case, the discovery pipeline for new treatments.Our project aim is to rapidly exploit a new family of probes and novel combinations of our existing probes. Our fluorescent reagents are chemically designed to enter cells and reveal changes brought about by a viral attack. Our patented technologies allow researchers to explore how a human cell responds to a viral attack and whether or not a new candidate drug can prevent the damage caused by that viral infection. The ultimate goal is to deliver screened and validated drugs that can halt disease progression and avoid long-term health consequences.